Skip to Main Content

Acceleron Pharma said Monday that a mid-stage clinical trial involving an experimental drug for pulmonary arterial hypertension achieved all its goals, potentially opening a new way to treat a rare and fatal disease that damages blood vessels in the lungs.

The Cambridge, Mass.-based biotech secured U.S. approval in November for its first drug, but building on that initial success with a second medicine has been a struggle. Monday’s positive results will need to be confirmed in larger studies, but should help ease investor concerns about Acceleron’s pipeline.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!